Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.
The gallbladder signal is real and it is mostly the weight loss, not the drug. Rapid loss increases biliary cholesterol saturation and reduces gallbladder motility, which is the classic recipe for stones — the same effect appears after bariatric surgery and in very-low-calorie dieting, without any GLP-1 involved. Trial data shows a modest absolute increase in cholelithiasis, concentrated in faster losers.
Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.
What I am after is how much of the gallbladder signal is the drug and how much is simply the rate of weight loss, because the answer changes what you can do about it. Tell me what I have not thought of.
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
PharmacoVig_BOS said:The gallbladder signal is real and it is mostly the weight loss, not the drug.
Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
PharmacoVig_BOS said:The gallbladder signal is real and it is mostly the weight loss, not the drug.
Pushing back on PharmacoVig_BOS here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
Ask again with the specifics and you will get a better answer than this one.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThis one has a reasonably settled answer, so here it is. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.
sarah.morrison said:Agreed, though "tolerable" needs defining.
All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.